CYCC Financial Facts
Grant revenue: 205KForeign exchange (losses)/gains: 51K
See Full Income Statement
Property, plant and equipment (net): 73K
Deficit accumulated during the development stage: -332.2M
See Full Balance Sheet
Cyclacel Pharmaceuticals (CYCC) Earnings
|
Expand Research on CYCC
| Next EPS Date | 5/8/24 *Est. | EPS Growth Rate | +100.0% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +3.3% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -2.0% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3/27/24 | Q423 | N/A | -$0.41 | N/A | N/A | N/A | N/A | N/A | N/A | ||
11/13/23  |
Q323 | N/A | -$0.36 | N/A | N/A | N/A | N/A | N/A | N/A | ||
| 8/9/23 | Q223 | -$0.44 | -$0.50 | +$0.06 | $370K | N/A | N/A |  | | Details | |
| 5/11/23 | Q123 | -$0.47 | -$0.67 | +$0.20 | N/A | N/A | N/A | | | Details | |
| 5/16/23 | Q123 | N/A | -$0.67 | N/A | N/A | N/A | N/A | N/A | N/A | ||
| 3/6/23 | Q422 | -$0.60 | -$0.48 | -$0.12 | N/A | N/A | N/A | | | Details | |
| 11/9/22 | Q322 | -$0.54 | -$0.52 | -$0.02 | N/A | N/A | N/A | | | Details | |
| 8/10/22 | Q222 | -$0.46 | -$0.54 | +$0.08 | N/A | N/A | N/A | | | Details |
